Current opinion in cardiology, epigenetics of heart failure

Purpose of review Heart failure is not simply a pump that has grown tired; it is a tissue that adapts and then, too often, becomes locked into its adaptations. This review examines how epigenetic regulation – chromatin accessibility, histone modifications, DNA methylation and hydroxymethylation, and the reader complexes that interpret these marks – converts transient stress into durable transcriptional programs. We focus on the mechanisms by which the failing heart acquires regulatory “memory,” and on the chromatin control nodes that are emerging as actionable targets for therapy and for biomarker development. Recent findings Three lines of evidence are reshaping the field. First, the failing-heart transcriptome is increasingly governed by a tractable set of chromatin control points: acetylation balance histone deacetylases (HDACs) versus histone acetyltransferases (HATs) such as p300/CREB-binding protein (CBP) and acetyl-lysine readers bromodomain and extraterminal (BET) proteins, including bromodomain-containing protein 4 (BRD4) that amplify hypertrophic, inflammatory, and profibrotic programs. Second, the adult human myocardium is not epigenetically inert: reproducible disease-associated methylation signatures and regulatory shifts are detectable across cardiomyopathy and ischemic heart failure, with early signals that some features may move with physiologic recovery. Third, acute stress phenotypes are being reframed as chromatin-state problems: Takotsubo syndrome compresses stress-to-dysfunction into days, and emerging mechanistic work supports an acetylation/deacetylation axis as a tractable regulatory lever in Takotsubo-like injury. Summary Epigenetics provides a mechanistic account of why cardiac injury can outlast its trigger and a rational route to intervention by targeting reader complexes, writer–eraser balance, and remodeler-mediated enhancer control. The translational mandate is precision: define causal regulatory nodes by cell type and disease phase and develop biomarkers that distinguish hemodynamic improvement from molecular reset.